

## HERSHKOVITZ & ASSOCIATES 1725 I STREET N.W. SUITE 300 WASHINGTON, DC 20006 703-323-9330

In re. Application of

: Nicolae MANOLESCU et al

Docket No.:P02250

Appln. No.

: 10/567,842

Group Art Unit: Unknown

Filed

: July 20, 2004

Examiner: Unknown

For : METHOD FOR IN VIVO DETERMINATION ON TESTED ANIMALS OF THE EFFICIENT CONCENTRATION OF DEUTERIUM DEPLETED WATER FOR CANCER

**THERAPY** 

**COMMISSIONER FOR PATENTS** 

P.O. Box 1450

Alexandria, Virginia 22313-1450

Sir:

Transmitted herewith is an IDS in the above-captioned application.

**X** Form PTO-1449

X Copies of references cited

The fee has been calculated as shown below:

Claims After	No. of Claims	Present	Small Er	ntity	Large Entity	
Amendment	Previously Paid	Extra				
					Rate	Fee
*Total Claims:			x 25=	\$ 0	x 50=	\$
**Indep. Claims:			x 100=	\$ 0	x 200=	\$
Multiple Dependent Claims Presented			+180=	\$	+360=	\$
Extension Fees for 1 Month			60	\$	120	\$
				\$		\$
			Total:	\$ 0	Total:	\$

<sup>\*</sup> If less than 20, write 20

\_\_Please charge my Deposit Account No. 50-2929 in the amount of \$ .

A Check in the amount of \$ \_\_ to cover the necessary fee is included.

X The U.S. Patent and Trademark Office is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 50-2929:

X Any additional filing fees required under 37 C.F.R. 1.16.

Any patent application processing fees under 37 C.F.R. 1.17, including any required extension of time fees in any concurrent or future reply requiring a petition for extension of time for its timely submission (37 CFR 1.136)(a)(3).

May 24, 2006

Date

Abraham Hershkovitz Reg. No. 45,294

<sup>\*\*</sup>If less than 3, write 3



P02250.A04

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Nicolae MANOLESCU et al

10/567,842

Group Art Unit: Unknown

Appln. No.:

Examiner: Unknown

Filed

July 20, 2004

Confirmation No.: 7147

For

METHOD FOR IN VIVO DETERMINATION ON TESTED ANIMALS

OF THE EFFICIENT CONCENTRATION OF DEUTERIUM DEPLETED

WATER FOR CANCER THERAPY

## INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to the duty of disclosure set forth in 37 CFR 1.56 and in accordance with the provisions of 37 CFR 1.97 and 1.98, the following information is brought to the attention of the Examiner for consideration during examination of the instant application.

Applicant submits herewith a copy of the International Search Report (in English) mailed on February 28, 2005 and conducted in International Application No. PCT/RO2004/000012 of which the instant application is the U.S. National stage. In particular, the International Examiner cited:

- Somlyai G et al: "The Biological Effects of Deuterium-Depleted Water, a (1) Possible New Tool in Cancer Therapy";
- (2) WO 95/18545; this document is also cited beginning in paragraph [0003] of

- the present application;
- (3) US 5,855,921 is cited beginning in paragraph [0009] of the present application;
- (4) RO 112422 is cited beginning in paragraph [0002] of the present application;
- (5) FR 2 552 324 is cited beginning in paragraph [0002] of the present application;
- (6) PCT WO 96/33129 is cited beginning in paragraph [0002] of the present application;
- (7) RU 2 182 562 is cited beginning in paragraph [0002] of the present application;
- (8) US 5,788,953 is cited beginning in paragraph [0003] of the present application;
- (9) WO 96/03996 is cited beginning in paragraph [0003] of the present application;
- (10) Billingham, R.E. et al., 1953 nature, 172, 603 is cited beginning in paragraph [0005] of the present application;
- (11) Miles, C.P., 1965, J Natl. cancer Inst. 34,103 is cited beginning in paragraph [0005] of the present application; and

P02250.A04

(12) Romanian Journal of Comparative Oncology, 4,295 is cited beginning in

paragraph [0005] of the present application.

Copies of the above-listed documents (1), (2), (4)-(7), (9), (10) and (12) are enclosed

herewith, as is a copy of the International Search Report and a completed copy of the PTO-

1449 form listing these documents. Copies of documents (3) and (8) are not provided since

they are U.S. patents readily available to the Examiner. A copy of document (11) is not yet

available and will be provided as soon as it can be obtained. Accordingly, the Examiner is

requested to consider these documents and to indicate such consideration by returning a

signed and initialed copy of the PTO-1449 form as part of the next official communication.

Please charge any additional fees necessary for consideration of the papers filed

herein and refund excess payments to Deposit Account No. 50-2929.

Questions related to this submission may be directed to the undersigned.

May 24, 2006

HERSHKOVITZ & ASSOCIATES

1725 I STREET, N.W.

**SUITE 300** 

WASHINGTON, DC 20006

Abraham Hershkovitz

Respectfully submitted, Nicolae MANOLESCU

Reg. No. 45,294

(703) 323-9330

(703) 323-6617 (FAX)

OIPE 49 8 W

				1 MM1 -	<i>E/</i> _				
	S	ubstitute for form I	2TO-144	9	APP	Comp	olete i	f Known	
INF	ORM	ATION D	ISC	LOSURE	Applica	tion Number	10/5	667,842	
QT.	TEM	ENT DV	ΛDE		Filing Date		July	20, 2004	
Substitute for form PTO-1449  INFORMATION DISCLOSU STATEMENT BY APPLICA				LICANI	First Named Inventor		Nicolae MANOLESC		
(Use as many sheets as necessary)							known		
(Use as many sneets as necessar)				isai y)	Examiner Name		Unknown		
Sheet	1		of	1	Attorney Docket Number		P02250		
			U	.S. PATENT D	OCU	MENTS			
Examiner	Cite Document Number			Publication Date		e of Patentee or	Pages, Columns, Lines, Where Relevant Passage or Relevant Figures Appear		
Initials* No.1		Number-Kind Code <sup>2</sup> (if known)		MM-DD-YYYY	Appl	Applicant of Cited Document			
	AA	US 5,788,953		08/04/1998	SO	MLYAI			
	AB	US 5,855,921		01/05/1999	SOMLYAI				
			FOR	EIGN PATEN	r DO	CUMENTS			
Examiner Initials*	Cite No.1	Foreign Patent (	eign Patent Document		Name of Patentee or Applicant of Cited Document			T <sup>6</sup>	
		Country Code <sup>3</sup> - Kind Code <sup>5</sup> ( <i>if kr</i>		4_			Relevant Passages or Relevant Figures Appear		
	BA	FR 2552324		03/29/1985	IO	IONESCU			
	BB	RO 112422		09/30/1997	ST	STEFANESCU et al			
	BC	RU 218256	RU 2182562 05/20/2002 SINJAK JU						
	BD	WO 96/03996		02/15/1996	BA	BAUER			
	BE	WO 95/185	45	07/13/1995	SO	MLYAI	-		
	BF	WO 963312	29	10/24/1996	KO	TAI			
	<u> </u>	NO	N PA	TENT LITERA	 TURE	DOCUMEN'	TS		<u> </u>
Examiner	Cite	Include name of	the auth	or (in CAPITAL LETTI	ERS), title	e of the article (who	en appro	opriate), title of the	T <sup>2</sup>
Initials*	No. <sup>1</sup>	item (book, magazine, journal, serial, symposiu number(s), publisher, city and/or country where				m, catalog, etc.), date, page(s), volume-issue published.			
	CA	Billingham			, p				
	СВ		<u> </u>	J Natl. cancer	Inst. 3	4.103			
	CC			al of Comparat		<del></del>			<u> </u>
	CD						um-D	epleted Water,	
l								-1	1
				ool in Cancer T	heran	v"			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.